Clinical Trials · NCT07668336
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 170
- Start date
- Jul 2026
- Locations
- 71 sites, 11 countries
- Primary endpoint
- Change from Baseline in Hemoglobin A1c (HbA1c)